Vaxcyte, Inc. (NASDAQ:PCVX) Shares Bought by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. increased its holdings in Vaxcyte, Inc. (NASDAQ:PCVX) by 3.5% during the fourth quarter, Holdings Channel reports. The firm owned 1,341,773 shares of the company’s stock after purchasing an additional 45,936 shares during the period. Charles Schwab Investment Management Inc.’s holdings in Vaxcyte were worth $109,838,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in PCVX. Natixis Advisors LLC lifted its position in shares of Vaxcyte by 61.1% during the 3rd quarter. Natixis Advisors LLC now owns 22,697 shares of the company’s stock valued at $2,594,000 after acquiring an additional 8,606 shares during the last quarter. Diversified Trust Co acquired a new stake in shares of Vaxcyte during the fourth quarter worth $1,433,000. Lisanti Capital Growth LLC lifted its holdings in shares of Vaxcyte by 68.1% during the third quarter. Lisanti Capital Growth LLC now owns 32,515 shares of the company’s stock valued at $3,715,000 after purchasing an additional 13,175 shares during the last quarter. Curi RMB Capital LLC acquired a new position in shares of Vaxcyte in the 3rd quarter valued at $903,000. Finally, WCM Investment Management LLC boosted its position in shares of Vaxcyte by 52.6% in the 3rd quarter. WCM Investment Management LLC now owns 140,847 shares of the company’s stock valued at $15,935,000 after purchasing an additional 48,543 shares during the period. 96.78% of the stock is owned by institutional investors and hedge funds.

Vaxcyte Stock Performance

Shares of PCVX opened at $71.18 on Friday. The company has a market capitalization of $9.17 billion, a PE ratio of -15.47 and a beta of 1.02. The company’s 50 day moving average price is $83.33 and its 200 day moving average price is $94.62. Vaxcyte, Inc. has a 52 week low of $58.10 and a 52 week high of $121.06.

Vaxcyte (NASDAQ:PCVX) last posted its quarterly earnings results on Tuesday, February 25th. The company reported ($1.02) EPS for the quarter, beating the consensus estimate of ($1.16) by $0.14. On average, equities analysts forecast that Vaxcyte, Inc. will post -4.21 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, COO Jim Wassil sold 8,000 shares of the business’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $73.27, for a total value of $586,160.00. Following the completion of the sale, the chief operating officer now owns 154,931 shares of the company’s stock, valued at approximately $11,351,794.37. The trade was a 4.91 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Grant Pickering sold 2,366 shares of the firm’s stock in a transaction that occurred on Monday, December 9th. The shares were sold at an average price of $92.25, for a total transaction of $218,263.50. Following the transaction, the chief executive officer now directly owns 136,215 shares in the company, valued at approximately $12,565,833.75. The trade was a 1.71 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 56,616 shares of company stock valued at $4,768,521 in the last three months. Insiders own 3.10% of the company’s stock.

Wall Street Analysts Forecast Growth

PCVX has been the topic of several recent analyst reports. Guggenheim restated a “buy” rating and set a $160.00 price objective on shares of Vaxcyte in a report on Wednesday, February 26th. Needham & Company LLC restated a “buy” rating and set a $140.00 price target on shares of Vaxcyte in a report on Wednesday, February 26th. Finally, The Goldman Sachs Group assumed coverage on shares of Vaxcyte in a research note on Friday, December 20th. They issued a “buy” rating and a $135.00 price objective for the company. Nine equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $147.50.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.